These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33509216)
1. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer. Zhang C; Zhao S; Wang X Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216 [TBL] [Abstract][Full Text] [Related]
2. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients. Li X; Chen L; Gu C; Sun Q; Li J PeerJ; 2020; 8():e9536. PubMed ID: 32874775 [TBL] [Abstract][Full Text] [Related]
3. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer. Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159 [TBL] [Abstract][Full Text] [Related]
4. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer. Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433 [TBL] [Abstract][Full Text] [Related]
5. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737 [TBL] [Abstract][Full Text] [Related]
6. Expression and Clinical Significance of Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949 [TBL] [Abstract][Full Text] [Related]
7. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979 [TBL] [Abstract][Full Text] [Related]
8. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Koh YW; Han JH; Haam S; Jung J; Lee HW Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074 [TBL] [Abstract][Full Text] [Related]
9. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma. Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349 [TBL] [Abstract][Full Text] [Related]
11. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma. Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537 [TBL] [Abstract][Full Text] [Related]
12. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma. Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462 [TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084 [TBL] [Abstract][Full Text] [Related]
14. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers. Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201 [TBL] [Abstract][Full Text] [Related]
15. CMTM6, a potential immunotherapy target. Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871 [TBL] [Abstract][Full Text] [Related]
16. Co-Expression with Membrane CMTM6/4 on Tumor Epithelium Enhances the Prediction Value of PD-L1 on Anti-PD-1/L1 Therapeutic Efficacy in Gastric Adenocarcinoma. Wang Z; Peng Z; Liu Q; Guo Z; Menatola M; Su J; Li T; Ge Q; Wang P; Shen L; Jin R Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680324 [TBL] [Abstract][Full Text] [Related]
17. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer. Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316 [TBL] [Abstract][Full Text] [Related]
18. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132 [TBL] [Abstract][Full Text] [Related]
19. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998 [TBL] [Abstract][Full Text] [Related]
20. The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer. Li B; Wu S; Qiu Z; Zhong X; Chen Z; Luo F; Li J; Liu K Neoplasma; 2022 May; 69(3):691-699. PubMed ID: 35293763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]